• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

IgA 肾病模型的启示。

Lessons from IgA Nephropathy Models.

机构信息

Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan.

Department of Nephrology, Juntendo University Urayasu Hospital, Chiba 279-0021, Japan.

出版信息

Int J Mol Sci. 2024 Oct 25;25(21):11484. doi: 10.3390/ijms252111484.

DOI:10.3390/ijms252111484
PMID:39519036
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11546737/
Abstract

IgA nephropathy (IgAN) is the most common type of primary glomerulonephritis worldwide; however, the underlying mechanisms of this disease are not fully understood. This review explores several animal models that provide insights into IgAN pathogenesis, emphasizing the roles of aberrant IgA1 glycosylation and immune complex formation. It discusses spontaneous, immunization, and transgenic models illustrating unique aspects of IgAN development and progression. The animal models, represented by the grouped ddY (gddY) mouse, have provided guidance concerning the multi-hit pathogenesis of IgAN. In this paradigm, genetic and environmental factors, including the dysregulation of the mucosal immune system, lead to increased levels of aberrantly glycosylated IgA, nephritogenic immune complex formation, and subsequent glomerular deposition, followed by mesangial cell activation and injury. Additionally, this review considers the implications of clinical trials targeting molecular pathways influenced by IgAN (e.g., a proliferation-inducing ligand [APRIL]). Collectively, these animal models have expanded the understanding of IgAN pathogenesis while facilitating the development of therapeutic strategies that are currently under clinical investigation. Animal-model-based studies have the potential to facilitate the development of targeted therapies with reduced side effects for IgAN patients.

摘要

IgA 肾病(IgAN)是全球最常见的原发性肾小球肾炎类型;然而,这种疾病的潜在机制尚未完全阐明。本综述探讨了几种动物模型,这些模型深入了解了 IgAN 的发病机制,强调了异常 IgA1 糖基化和免疫复合物形成的作用。文中讨论了自发性、免疫接种和转基因模型,这些模型说明了 IgAN 发展和进展的独特方面。以分组 ddY(gddY)小鼠为代表的动物模型为 IgAN 的多打击发病机制提供了指导。在这种模式下,遗传和环境因素,包括黏膜免疫系统的失调,导致异常糖基化 IgA 的水平升高、肾炎性免疫复合物的形成以及随后的肾小球沉积,接着是系膜细胞的激活和损伤。此外,本综述还考虑了针对 IgAN 影响分子途径的临床试验的意义(例如,增殖诱导配体 [APRIL])。总之,这些动物模型扩展了对 IgAN 发病机制的理解,同时促进了治疗策略的发展,这些策略目前正在临床研究中。基于动物模型的研究有可能为 IgAN 患者开发具有较少副作用的靶向治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5653/11546737/ecee6cd11e95/ijms-25-11484-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5653/11546737/3c9376b987d7/ijms-25-11484-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5653/11546737/ecee6cd11e95/ijms-25-11484-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5653/11546737/3c9376b987d7/ijms-25-11484-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5653/11546737/ecee6cd11e95/ijms-25-11484-g002.jpg

相似文献

1
Lessons from IgA Nephropathy Models.IgA 肾病模型的启示。
Int J Mol Sci. 2024 Oct 25;25(21):11484. doi: 10.3390/ijms252111484.
2
Murine Models of Human IgA Nephropathy.人类 IgA 肾病的鼠类模型。
Semin Nephrol. 2018 Sep;38(5):513-520. doi: 10.1016/j.semnephrol.2018.05.021.
3
A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy.靶向增殖诱导配体(APRIL)的抗体是治疗小鼠 IgA 肾病的一种安全有效的方法。
Kidney Int. 2019 Jul;96(1):104-116. doi: 10.1016/j.kint.2019.01.031. Epub 2019 Mar 16.
4
Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy.斯巴森坦可改善 IgA 肾病小鼠模型中由 IgA1-IgG 免疫复合物引起的肾小球细胞过度增生和炎症基因网络。
Am J Physiol Renal Physiol. 2024 May 1;326(5):F862-F875. doi: 10.1152/ajprenal.00253.2023. Epub 2024 Mar 21.
5
TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy.Toll样受体9(TLR9)激活通过APRIL和白细胞介素-6(IL-6)介导的途径在IgA肾病中诱导异常的IgA糖基化。
Kidney Int. 2020 Feb;97(2):340-349. doi: 10.1016/j.kint.2019.08.022. Epub 2019 Sep 5.
6
Aberrantly glycosylated IgA1 as a factor in the pathogenesis of IgA nephropathy.异常糖基化的IgA1作为IgA肾病发病机制中的一个因素。
Clin Dev Immunol. 2011;2011:470803. doi: 10.1155/2011/470803. Epub 2011 Jan 24.
7
LPS/TLR4 Pathway Regulates IgA1 Secretion to Induce IgA Nephropathy.LPS/TLR4 通路调控 IgA1 分泌诱导 IgA 肾病。
Altern Ther Health Med. 2024 Jan;30(1):419-425.
8
B cell targeting in IgA nephropathy.IgA肾病中的B细胞靶向治疗。
Nephrology (Carlton). 2024 Sep;29 Suppl 2:39-43. doi: 10.1111/nep.14367.
9
Aberrant Glycosylation of the IgA1 Molecule in IgA Nephropathy.IgA 肾病中 IgA1 分子的异常糖基化。
Semin Nephrol. 2018 Sep;38(5):461-476. doi: 10.1016/j.semnephrol.2018.05.016.
10
Pathogenesis of IgA nephropathy.IgA肾病的发病机制。
Ann Med Interne (Paris). 1999 Feb;150(2):91-8.

本文引用的文献

1
Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy.斯巴森坦可改善 IgA 肾病小鼠模型中由 IgA1-IgG 免疫复合物引起的肾小球细胞过度增生和炎症基因网络。
Am J Physiol Renal Physiol. 2024 May 1;326(5):F862-F875. doi: 10.1152/ajprenal.00253.2023. Epub 2024 Mar 21.
2
Oral bacteria induce IgA autoantibodies against a mesangial protein in IgA nephropathy model mice.口腔细菌诱导 IgA 肾病模型小鼠系膜蛋白的 IgA 自身抗体。
Life Sci Alliance. 2024 Feb 8;7(4). doi: 10.26508/lsa.202402588. Print 2024 Apr.
3
Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy.
斯巴森坦在 IgA 肾病的 gddY 小鼠模型中优于洛沙坦。
Nephrol Dial Transplant. 2024 Aug 30;39(9):1494-1503. doi: 10.1093/ndt/gfae021.
4
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.在 IgA 肾病患者中,sparsentan 对比厄贝沙坦的疗效和安全性(PROTECT):一项随机、活性对照、3 期临床试验的 2 年结果。
Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3.
5
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.Sibeprenlimab 治疗 IgA 肾病患者的 II 期临床试验。
N Engl J Med. 2024 Jan 4;390(1):20-31. doi: 10.1056/NEJMoa2305635. Epub 2023 Nov 2.
6
The nucleotide-sensing Toll-Like Receptor 9/Toll-Like Receptor 7 system is a potential therapeutic target for IgA nephropathy.核苷酸感应性Toll样受体9/Toll样受体7系统是IgA肾病的一个潜在治疗靶点。
Kidney Int. 2023 Nov;104(5):943-955. doi: 10.1016/j.kint.2023.08.013. Epub 2023 Aug 28.
7
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.斯巴森坦治疗 IgA 肾病患者:一项随机、双盲、活性对照临床试验的预先指定中期分析。
Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1.
8
Identification of IgA autoantibodies targeting mesangial cells redefines the pathogenesis of IgA nephropathy.针对系膜细胞的 IgA 自身抗体的鉴定重新定义了 IgA 肾病的发病机制。
Sci Adv. 2023 Mar 22;9(12):eadd6734. doi: 10.1126/sciadv.add6734.
9
Glomerular deposition of galactose-deficient IgA1-containing immune complexes via glomerular endothelial cell injuries.通过肾小球内皮细胞损伤导致半乳糖缺陷 IgA1 免疫复合物在肾小球沉积。
Nephrol Dial Transplant. 2022 Aug 22;37(9):1629-1636. doi: 10.1093/ndt/gfac204.
10
Immunoglobulin A nephropathy is characterized by anticommensal humoral immune responses.免疫球蛋白 A 肾病的特征是针对共生体的体液免疫反应。
JCI Insight. 2022 Mar 8;7(5):e141289. doi: 10.1172/jci.insight.141289.